Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 March 2022 | Story Dr Nitha Ramnath | Photo istock
Online news

The University of the Free State (UFS) has joined The Conversation Africa (TCA) as a funding partner.  TCA, a not-for-profit media initiative, is part of a global platform that publishes articles written by academics and researchers.  The platform’s objective is to make the knowledge produced in the academy accessible, easy to understand, and freely available to the general public. Articles are published daily on the TC-Africa website - https://theconversation.com/africa. 

The platform uses a Creative Commons republishing model. This means articles can be republished by other media on the continent and internationally, ensuring even greater reach to audiences including academics, policy makers, funders, and the general public. 

To date, more than 55 UFS researchers and academics have published with TCA, and their articles have garnered more than 1,3 million readers globally. UFS researchers and academics are encouraged to publish with The Conversation. 

As part of the partnership, TCA will run writing workshops for UFS academics and researchers who want to enhance their writing and science communication skills. Dates for these will be announced soon.

How you can publish with The Conversation Africa

• Engage with The Conversation Africa editors when they contact you directly to write about your research area and expertise. The articles are short, ± 800 to 1 000 words.

• Pitch your idea for an article directly to The Conversation Africa here   

• Register as an author, and set up a profile

• Engage with the Communication and Research offices. Every week, The Conversation Africa sends an expert request for expert authors on topical issues to the Communication and Research offices, which can identify researchers. 
- Interested researchers are put into contact with the relevant editor at The Conversation to discuss the potential article

Why should you get published on The Conversation Africa?

Benefits for researchers and academics:

• Articles on the platform help to raise the profile of academics, often leading to policy engagement with governments, businesses, industry or professional bodies, conference invitations, academic collaborations, and further media exposure. 
• In the course of writing, academics get bespoke editorial assistance from the team working in consultation with them. 
• The opportunity to take part in a hands-on science communication writing workshop.
• Readership and republication metrics for each published article.
• A global readership with up to 1,2 million readers monthly.

Benefits for Communication and Marketing and the Research office:

• Provides well-curated, ready-to-use communication material for websites and social media. 
• Helps to profile the work of the university for marketing, communication, and awareness.
• Provides media exposure to the talent pool of UFS academics and researchers. 

Benefits for and across the university:

• Shines a spotlight on the excellent research and innovation at the UFS.
• Demonstrates the UFS’ commitment to facilitating greater engagement with society and promoting interdisciplinary communications.
• Visibility for the institution and researchers nationally and globally.
• Access to institutional analytics, including detailed data on the content published by UFS researchers.

Contact The Conversation Africa:

To arrange departmental meetings and introductory sessions to The Conversation Africa team, contact: Pfungwa Nyamukachi, Strategic Partnerships and Stakeholder Relations Manager: pfungwa.nyamukachi@theconversation.com 

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept